TVRD News - Candlesense

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, s...

Conference

1 day ago

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

How might the REVERT IPF trial results influence the valuation of Tvardi's stock relative to peers in the biotech sector? Will the company provide guidance on future enrollment milestones or subsequent trial phases for TTI-101? What regulatory milestones (e.g., IND filing, FDA meetings) are anticipated before potential Phase 3 initiation?

Earnings

8 days ago